| | 194804-75-6 Basic information More.. |
| Product Name: | Garenoxacin | | Synonyms: | 1-Cyclopropyl-8-(difluoroMethoxy)-7-[(1R)-2,3-dihydro-1-Methyl-1H-isoindol-5-yl]-1,4-dihydro-4-oxo-3-quinolinecarboxylic Acid;Ganefloxacin;(R)-1-Cyclopropyl-8-(difluoroMethoxy)-7-(1-Methylisoindolin-5-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid;(R)-1-Cyclopropyl-8-(difluoromethoxy)-7-(1-methylisoindolin-5-yl)-4-oxo-1,4-dihydroquinoline-3-ca;GARENOXACIN HBR;Garenoxacin;1-Cyclopropyl-8-(difluoromethoxy)-7-[(1R)-1-methyl-2,3-dihydro-1H-isoindol-5-yl]-4-oxoquinoline-3-carboxylic acid;1-Cyclopropyl-8-(difluoromethoxy)-7-[(1R)-(1-methyl-2,3-dihydro-1H-5-isoindolyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid | | CAS: | 194804-75-6 | | MF: | C23H20F2N2O4 | | MW: | 426.41 | | EINECS: | | | Mol File: | 194804-75-6.mol |  |
Use
Garenoxacin is a new quinolone antimicrobial agent that exhibits a broad spectrum of activity against both Gram-negative and Gram-positive organisms, including the important community-acquired respiratory pathogens S.pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. In addition, it has potent activity against several resistant strains such as multidrug-resistant S.pneumoniae, methicillin-resistant S.aureus (MRSA), and vancomycin-resistant enterococci (VRE). It was launched in Japan as an oral treatment for respiratory tract and otorhinolaryngological infections.
- Garenoxacin
-
- US $0.00-0.00 / G
- 2023-04-20
- CAS:194804-75-6
- Min. Order: 1G
- Purity: 99.99％
- Supply Ability: 1KGS
- Garenoxacin
-
- US $0.00-0.00 / kg
- 2022-09-23
- CAS:194804-75-6
- Min. Order: 1kg
- Purity: 98%
- Supply Ability: 1Ton
- Garenoxacin USP/EP/BP
-
- US $1.10 / g
- 2021-07-22
- CAS:194804-75-6
- Min. Order: 1g
- Purity: 99.9%
- Supply Ability: 100 Tons min
|
|
194804-75-6
Recommend Suppliers |
|